CDER Conversations
The Office of New Drugs' Efforts to Expand Regulatory Science Research
CDER’s Office of New Drugs (OND) developed a research program in 2018 to centralize and enhance its regulatory science research activities. Recently, the OND Research Program (OND-RP) published its first two fiscal year annual reports, the Extramural Research Outcomes Report and the ORISE Fellowship Research Outcomes Report, which highlight the research projects that the OND-RP funded.
In this CDER Conversation, Laura Jaeger, PhD, associate director of the OND-RP, talks about the program’s important work.